Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dabigatran→

Dabigatran Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
211914-51-1
Molecular formula
C25H25N7O3
Molecular weight
471.5 g/mol
Drug class
Direct thrombin inhibitoractive moiety released from dabigatran etexilate prodrug
Mechanism of action
Directly and competitively inhibits free and clot-bound thrombin (factor IIa), preventing fibrin formation and thrombin-mediated platelet activation. In clinical products, dabigatran is delivered as the active metabolite after hydrolysis of dabigatran etexilate.
Indications / reported uses
  • Prevention of stroke and systemic embolism in eligible adults with non-valvular atrial fibrillation
  • Treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) after initial parenteral anticoagulation and reduction of recurrence risk
  • Prevention of venous thromboembolism following hip replacement surgery in adults; specific indications, age criteria and renal-dose restrictions are label-specific

Sources: US DailyMed — PRADAXA (dabigatran etexilate) · EMA EPAR — Pradaxa · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dabigatran Environmental Risk Assessment (ERA) (the Dabigatran ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.